Evidence map›Paper›PMID 28289374›Full record

ArticleFrontiers in molecular neuroscience2017

Discovery of Compounds that Positively Modulate the High Affinity Choline Transporter.

Parul Choudhary, Emma J Armstrong, Csilla C Jorgensen, Mary Piotrowski, Maria Barthmes, Rubben Torella, Sarah E Johnston, Yuya Maruyama, John S Janiszewski, R Ian Storer and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 4 countries.

Parul ChoudharyPfizer Neusentis, Cambridge, UK.
Emma J ArmstrongPfizer Neusentis, Cambridge, UK.
Csilla C JorgensenPrimary Pharmacology Group, Pfizer Inc. Groton, CT, USA.
Mary PiotrowskiPrimary Pharmacology Group, Pfizer Inc. Groton, CT, USA.
Maria BarthmesNanion Technologies Munich, Germany.
Rubben TorellaPfizer, Worldwide Medicinal Chemistry Cambridge, UK.
Sarah E JohnstonPfizer Neusentis, Cambridge, UK.
Yuya MaruyamaCentral Research Laboratory, Kissei Pharmaceutical Co., Ltd. Nagano, Japan.
John S JaniszewskiPrimary Pharmacology Group, Pfizer Inc. Groton, CT, USA.
R Ian StorerPfizer, Worldwide Medicinal Chemistry Cambridge, UK.
Sarah E SkerrattPfizer, Worldwide Medicinal Chemistry Cambridge, UK.
Caroline L BennPfizer Neusentis, Cambridge, UK.
Pfizer (United Kingdom) · GBPfizer (United States) · USKissei Pharmaceutical (Japan) · JPNanion (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholinergic hypofunction is associated with decreased attention and cognitive deficits in the central nervous system in addition to compromised motor function. Consequently, stimulation of cholinergic neurotransmission is a rational therapeutic approach for the potential treatment of a variety of neurological conditions. High affinity choline uptake (HACU) into acetylcholine (ACh)-synthesizing neurons is critically mediated by the sodium- and pH-dependent high-affinity choline transporter (CHT, encoded by the

Indexed as

acetylcholineHACU (high affinity choline uptake)mass spectrometryphenotypic screeningSLC5A7small molecule screeningsolute carrierSSM electrophysiology

Identifiers

PMID28289374
PMCPMC5326799
OpenAlexW2589906018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.